1. Why this matters for MRCGP

• Hypertension is a classic AKT topic: thresholds, staging, ambulatory/home monitoring, drug steps and targets are highly testable.
• In SCA, it often appears as a raised clinic BP, home BP discussion, treatment choice, adherence problem or severe reading.
• The GP risk is either over-treating a single clinic reading, or missing severe hypertension, target organ damage or secondary causes.
• Practical use matters because diagnosis and monitoring depend on correct BP measurement, ABPM/HBPM and safe drug monitoring.

2. GP Bottom Line

• Do not diagnose from one clinic reading: suspect at clinic BP ≥140/90 mmHg, confirm with ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM).
• BP ≥180/120 mmHg needs same-day specialist assessment if there are retinal signs or life-threatening symptoms. Suspected phaeochromocytoma also needs same-day specialist assessment, even if the BP is labile rather than persistently ≥180/120.
• While confirming diagnosis, assess target organ damage and cardiovascular disease (CVD) risk.
• Treatment is staged: lifestyle for all; drug treatment depends on stage, age, CVD risk, target organ damage, diabetes, renal disease and preference.
• Exam trap: Step 4 resistant hypertension is not “just add another drug” — confirm BP with ABPM/HBPM, assess postural hypotension and discuss adherence first.

3. 60 Second Exam Snapshot

• Confirm hypertension with clinic BP ≥140/90 plus ABPM/HBPM average ≥135/85.
• Stage 1: clinic 140/90–159/99 plus ABPM/HBPM 135/85–149/94.
• Stage 2: clinic ≥160/100 but <180/120 plus ABPM/HBPM ≥150/95.
• Severe hypertension: clinic systolic ≥180 or diastolic ≥120.
• Baseline hypertension assessment: urine albumin:creatinine ratio (ACR) and haematuria, HbA1c, electrolytes, creatinine/eGFR, total cholesterol and HDL cholesterol, fundi and 12-lead ECG. Use clinic BP for cardiovascular disease (CVD) risk.
• Under 80 target: clinic <140/90; ABPM/HBPM <135/85.
• Age 80+: clinic <150/90; ABPM/HBPM <145/85.
• First-line drug choice pivots on age, type 2 diabetes and Black African/African-Caribbean family origin.

4. Recognition and Diagnosis

• Hypertension is persistently raised arterial BP and is usually found by measurement rather than symptoms. It increases risk of heart failure, coronary artery disease, stroke, chronic kidney disease, peripheral arterial disease and vascular dementia.
• Measure BP properly: quiet seated patient, supported arm, appropriate cuff. Measure both arms when considering diagnosis. If the inter-arm difference is >15 mmHg, repeat; if still >15 mmHg, use the higher-reading arm for future readings.
• Palpate the radial or brachial pulse first. If the pulse is irregular, automated devices may be inaccurate, so measure manually by direct auscultation over the brachial artery.
• In postural symptoms, type 2 diabetes or age 80 and over, measure seated or lying BP, then standing BP after at least 1 minute. A fall of systolic BP ≥20 mmHg or diastolic BP ≥10 mmHg changes management: review likely causes, measure subsequent BP standing, and consider specialist referral if symptoms persist despite addressing causes.
• If clinic BP is ≥140/90, repeat during the consultation; if the second reading is substantially different, take a third. Record the lower of the last two readings.
• Use ABPM if clinic BP is ≥140/90 but <180/120; use HBPM if ABPM is unsuitable or not tolerated. If clinic BP is ≥180/120, follow the severe hypertension pathway first.
• Suspect white-coat effect if clinic and out-of-clinic readings differ by more than 20/10 mmHg. Masked hypertension is the opposite pattern: clinic BP normal but out-of-clinic readings higher.
• Suspect secondary hypertension especially under age 40, sudden worsening, accelerated hypertension, resistant hypertension, suggestive history/examination/investigation findings, or a medicine/substance cause.
• Ask about current medicines and substances that may raise BP, such as NSAIDs, combined oral contraceptive, corticosteroids, ADHD stimulants or sympathomimetics, venlafaxine, alcohol, cocaine/amphetamine use, ciclosporin, erythropoietin, leflunomide or liquorice/herbal medicines.

5. AKT Essentials: What Changes the Answer

Diagnosis / recognition

• ABPM: at least 2 readings per hour during usual waking hours; use average of at least 14 readings.
• HBPM: 2 seated readings at least 1 minute apart, twice daily, ideally morning and evening, for at least 4 days and ideally 7; discard day 1 and average the rest.
• Severe hypertension without emergency features still needs target-organ assessment as soon as possible.

Investigation / interpretation

• Use clinic BP for formal CVD risk calculation.
• QRISK3 is supported for adults aged 25–84 without CVD and for type 2 diabetes aged 25–84.
• Do not use CVD risk tools in high-risk groups listed in the source, including type 1 diabetes, eGFR <60 ml/min/1.73 m² and/or albuminuria.

Management / next best step

• Persistent stage 2: offer antihypertensive drug treatment plus lifestyle advice, regardless of age; use judgement in frailty/multimorbidity.
• Persistent stage 1 under 80: discuss drugs if target organ damage, established CVD, renal disease, diabetes or 10-year CVD risk ≥10%.
• Stage 1 under 60 with CVD risk <10%: consider treatment because 10-year risk may underestimate lifetime risk.
• Age over 80 with stage 1: consider treatment if clinic BP >150/90.
• Isolated systolic hypertension, with systolic BP ≥160 mmHg, is treated using the same pathway as combined systolic and diastolic hypertension.

Medicines / safety

• Angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB): Step 1 if type 2 diabetes, or age under 55 and not Black African/African-Caribbean family origin.
• Calcium-channel blocker (CCB): Step 1 if age 55+ without type 2 diabetes, or Black African/African-Caribbean family origin without type 2 diabetes.
• Consider ARB in preference to ACE inhibitor in Black African/African-Caribbean family origin.
• Do not combine ACE inhibitor and ARB for hypertension.
• If ACE inhibitor cough: offer ARB. If CCB oedema: offer thiazide-like diuretic.
• Starting/changing diuretic: prefer thiazide-like diuretic such as indapamide over bendroflumethiazide or hydrochlorothiazide.

Follow-up / monitoring

• ACE inhibitor or ARB: check renal function/electrolytes before, 1–2 weeks after starting and after each dose increase, then annually unless more frequent checks are needed.
• Step 4 spironolactone: only if potassium ≤4.5 mmol/L; monitor sodium, potassium and renal function within 1 month and repeat as needed.
• Annual review: check BP, adherence, symptoms, treatment tolerability and lifestyle; check creatinine/eGFR, electrolytes and urine ACR; reassess CVD risk if not on an antiplatelet or statin. If BP is above target, confirm it is persistently raised by repeat readings over the next few weeks or months, or consider ABPM/HBPM if white-coat effect is suspected.

6. SCA Consultation Essentials

Likely tasks: explain a high BP reading, arrange ABPM/HBPM, discuss starting medication, manage side effects, or review uncontrolled BP.

Ask specifically about:

• chest pain, new confusion, signs of heart failure, possible acute kidney injury;
• headache, palpitations, pallor, abdominal pain or sweating attacks suggesting phaeochromocytoma;
• postural dizziness or falls;
• current medicines and substances that may raise BP, such as NSAIDs, combined oral contraceptive, corticosteroids, ADHD stimulants or sympathomimetics, venlafaxine, alcohol, cocaine/amphetamine use, ciclosporin, erythropoietin, leflunomide or liquorice/herbal medicines;
• pregnancy, planning pregnancy or breastfeeding before ACE inhibitor/ARB;
• adherence before escalating treatment;
• diet, salt, caffeine, alcohol, activity, weight and smoking.

Useful patient framing: “One clinic reading is not enough. We need home or 24-hour readings to see what your usual blood pressure is.”

Medicine explanation can use source-supported examples: ACE inhibitors often end in “pril” such as ramipril, lisinopril or perindopril; ARBs often end in “artan” such as losartan, candesartan or valsartan; CCBs often end in “dipine” such as amlodipine, felodipine or lacidipine; indapamide is a diuretic example.

7. Red Flags / Escalation / Referral

Arrange same-day specialist assessment for:

• clinic BP ≥180/120 mmHg with retinal haemorrhage or papilloedema;
• clinic BP ≥180/120 mmHg with life-threatening symptoms such as new confusion, chest pain, signs of heart failure or acute kidney injury;
• suspected phaeochromocytoma, for example labile or postural hypotension, headache, palpitations, pallor, abdominal pain or diaphoresis.

If BP ≥180/120 but no same-day referral features:

• assess target organ damage as soon as possible;
• if target organ damage is found, consider starting antihypertensive treatment immediately without waiting for ABPM/HBPM;
• if no target organ damage, repeat clinic BP within 7 days or consider ABPM/HBPM with clinical review within 7 days.

For adults under 40 with hypertension, consider specialist evaluation for secondary causes and treatment benefit-risk assessment.

8. What the GP Should Do Today

• Assess: repeat clinic BP correctly; check both arms; palpate pulse; ask about postural symptoms and urgent features.
• Examine: if severe BP, check for retinal haemorrhage or papilloedema where clinically appropriate.
• Confirm: arrange ABPM, or HBPM if ABPM unsuitable, for clinic BP ≥140/90 but <180/120. If clinic BP is ≥180/120, follow the severe hypertension pathway first.
• Investigate: urine ACR and haematuria; HbA1c; electrolytes, creatinine and eGFR; total cholesterol and HDL cholesterol; fundi; 12-lead ECG.
• Risk-assess: estimate CVD risk using clinic BP where appropriate.
• Advise: lifestyle advice on diet/exercise, weight if relevant, salt reduction, smoking cessation, alcohol and caffeine. Avoid potassium chloride salt substitutes in older people, diabetes, pregnancy, kidney disease and people taking ACE inhibitors or ARBs.
• Treat: apply treatment thresholds and stepwise medicines after diagnosis, or earlier in severe hypertension with target organ damage as above.
• Review: annual review should check BP, adherence, symptoms, treatment tolerability and lifestyle; check creatinine/eGFR, electrolytes and urine ACR; reassess CVD risk if not on an antiplatelet or statin. If BP is above target, confirm it is persistently raised by repeat readings over the next few weeks or months, or consider ABPM/HBPM if white-coat effect is suspected.

9. Practical Use in GP: How to Apply This Topic

Before measurement

• Use a validated BP device; clinical devices should be maintained and recalibrated according to manufacturer instructions.
• Use appropriate cuff size and a relaxed setting.
• If pulse irregularity is present, use manual auscultation.
• For postural symptoms, type 2 diabetes or age 80 and over, measure seated or lying BP, then standing BP after at least 1 minute. A fall of systolic BP ≥20 mmHg or diastolic BP ≥10 mmHg changes management.

ABPM/HBPM

• ABPM confirms diagnosis using waking-hours averages.
• HBPM requires training and clear advice about what to do if readings are not achieving target.
• HBPM diagnostic schedule: 2 readings, 1 minute apart, twice daily, at least 4 days and ideally 7; discard day 1.

Home monitors

• Use British and Irish Hypertension Society-approved monitors.
• Home monitors should be replaced after a maximum of 4 years, sooner if damaged or accuracy is doubted.
• Wearable BP devices are not endorsed in the supplied BIHS text.

Community pharmacy

• Free pharmacy checks are described for eligible adults aged 40 or over in England.
• High readings may lead to pharmacy ABPM or GP referral.
• Very high pharmacy readings lead to urgent GP referral within 24 hours.

10. Medicines, Investigations and Intervention Safety

ACE inhibitors / ARBs

• Used in Step 1 for type 2 diabetes or age under 55 not of Black African/African-Caribbean family origin.
• Check renal function and electrolytes before and after initiation/dose changes.
• Avoid ACE inhibitor + ARB combination for hypertension.
• Do not use in pregnancy, planning pregnancy or breastfeeding unless essential and risks/benefits are discussed.
• ACE inhibitor cough: consider an ARB if troublesome and other causes are ruled out.
• ACE inhibitor angio-oedema: stop the ACE inhibitor immediately and, if possible, avoid switching to an ARB because ARBs can also trigger angio-oedema.

CCBs

• Used first-line in age 55+ without type 2 diabetes, or Black African/African-Caribbean family origin without type 2 diabetes. Amlodipine is a source-supported example.
• CCB oedema supports switching to thiazide-like diuretic.
• CCBs are generally not used in heart failure in the source text except specific caveats.

Thiazide-like diuretics

• Indapamide is the key example. Prefer thiazide-like diuretic when starting/changing diuretic treatment. Continue bendroflumethiazide or hydrochlorothiazide if BP is stable and well controlled.
• Thiazide-like diuretics: check sodium, potassium and renal function before treatment and monitor subsequently, with more frequent checks in higher-risk patients according to clinical judgement.
• Avoid/caution applies in electrolyte disturbance, gout, diabetes, systemic lupus erythematosus, severe renal impairment and pregnancy as specified.

Step 4 resistant hypertension

• Before Step 4: confirm raised BP with ABPM/HBPM, assess postural hypotension and discuss adherence.
• If potassium ≤4.5 mmol/L, consider low-dose spironolactone; monitor sodium, potassium and renal function within 1 month.
• If potassium >4.5 mmol/L, consider alpha-blocker or beta-blocker.
• If uncontrolled on 4 drugs, seek specialist advice.

Safety details worth remembering

• Spironolactone plus ACE inhibitor/ARB increases severe hyperkalaemia risk.
• Amlodipine has been confused with atenolol and nimodipine; atenolol has been confused with amlodipine.
• Hydrochlorothiazide containing products have MHRA advice on cumulative dose-dependent non-melanoma skin cancer risk; this matters if a patient is already taking it.

11. How to Explain It to the Patient

“High blood pressure often has no symptoms, so the only reliable way to know is to measure it properly.”

“A single surgery reading can be misleading, so we confirm it with home or 24-hour readings.”

“The aim is not just to lower a number; it is to reduce your chance of stroke, heart attack, heart failure and kidney or eye damage.”

“Lifestyle changes can help, and medicines can be added if your stage or overall risk means the benefits are likely to outweigh the downsides.”

“Some blood pressure medicines need blood tests to check kidney function and salts in the blood.”

“If you get chest pain or discomfort that does not go away, call 999. If your blood pressure is very high and you develop new confusion or other urgent symptoms we have discussed, you need same-day medical assessment.”

12. When the Plan Changes

• If clinic BP is ≥180/120 with retinal signs or life-threatening symptoms.
  • Why this changes the plan: This is not routine confirmation.
  • What the GP does now: Same-day specialist assessment.
• If clinic BP is ≥180/120 without same-day features.
  • Why this changes the plan: Target organ damage determines urgency of treatment.
  • What the GP does now: Investigate target organ damage as soon as possible and review/confirm within 7 days if none found.
• If the patient is under 40.
  • Why this changes the plan: Secondary causes and long-term treatment balance need consideration.
  • What the GP does now: Consider specialist evaluation.
• If Step 1 treatment is needed.
  • Why this changes the plan: Age, type 2 diabetes and family origin change drug class.
  • What the GP does now: Choose ACE inhibitor/ARB or CCB according to the source-supported pathway.
• If BP is uncontrolled on optimal tolerated doses of an ACE inhibitor or ARB plus a CCB plus a thiazide-like diuretic.
  • Why this changes the plan: This is resistant hypertension.
  • What the GP does now: Confirm with ABPM/HBPM, assess postural hypotension and discuss adherence before Step 4 treatment or specialist advice.

13. Common AKT / SCA Traps

• Diagnosing hypertension from one clinic BP.
• Forgetting that home/ambulatory readings use lower thresholds than clinic readings — but staging still needs the exact source thresholds.
• Missing same-day referral triggers at BP ≥180/120.
• Sending all severe hypertension automatically same day without checking target-organ damage pathway.
• Using ABPM/HBPM instead of clinic BP for CVD risk calculation.
• Escalating drugs without checking adherence.
• Combining ACE inhibitor with ARB.
• Starting spironolactone when potassium is >4.5 mmol/L.
• Missing pregnancy/planning pregnancy/breastfeeding before ACE inhibitor or ARB.
• Endorsing wearable BP devices or named home monitor models without checking validation.

14. Common Exam Angles

• Angle: Raised clinic BP at routine appointment.
  • Hidden challenge: Repeat correctly and confirm with ABPM/HBPM.
  • What the candidate must not miss: Target-organ tests while awaiting confirmation.
• Angle: BP 185/122 in surgery.
  • Hidden challenge: Severe hypertension is pathway-dependent.
  • What the candidate must not miss: Retinal signs, life-threatening symptoms and phaeochromocytoma features.
• Angle: Starting first antihypertensive.
  • Hidden challenge: Age, type 2 diabetes and family origin change Step 1.
  • What the candidate must not miss: ACE inhibitor/ARB pregnancy and renal monitoring safety.
• Angle: BP uncontrolled despite optimal tolerated doses of ACE inhibitor or ARB plus CCB plus thiazide-like diuretic.
  • Hidden challenge: Resistant hypertension work-up before Step 4.
  • What the candidate must not miss: ABPM/HBPM confirmation, postural BP and adherence.

15. 90 Second Audio Summary Script

Hypertension in UK primary care is about thresholds, confirmation and risk. Suspect it when clinic BP is 140 over 90 or higher, but do not diagnose from one clinic reading. Repeat the reading properly, use the lower of the last two, and confirm with ambulatory monitoring or home monitoring. Home and ambulatory thresholds are lower: 135 over 85 confirms hypertension when clinic BP is at least 140 over 90.

Stage 1 is clinic 140 over 90 to 159 over 99 with home or ambulatory 135 over 85 to 149 over 94. Stage 2 is clinic 160 over 100 or higher but below 180 over 120, with home or ambulatory 150 over 95 or higher. Severe hypertension is clinic systolic 180 or diastolic 120.

Baseline hypertension assessment includes urine albumin:creatinine ratio, or ACR, and haematuria, HbA1c, renal function and electrolytes, total cholesterol and HDL cholesterol, fundi and ECG. Use clinic BP for cardiovascular disease, or CVD, risk.

BP 180 over 120 or higher needs same-day specialist assessment if there are retinal signs or life-threatening symptoms. Suspected phaeochromocytoma also needs same-day specialist assessment, even if BP is labile rather than persistently 180 over 120 or higher. If severe BP has none of these features, investigate target organ damage quickly and review within 7 days if none is found.

Treat stage 2 with lifestyle plus medication. For stage 1, treatment depends on age, target organ damage, CVD, renal disease, diabetes and CVD risk. Drug choice is stepwise: ACE inhibitor or ARB for type 2 diabetes or under 55 not Black African or African-Caribbean; CCB for age 55 or over without type 2 diabetes, or Black African/African-Caribbean without type 2 diabetes. Never combine ACE inhibitor and ARB. Check renal function and electrolytes for ACE inhibitors, ARBs, diuretics and spironolactone where specified.

References

• British and Irish Hypertension Society (BIHS) (no date) Validated BP monitors: clinical, policy, and procurement guidance. Available at: (Accessed: 28 April 2026).
• Hodgkinson, J.A., Lee, M.M., Milner, S., Bradburn, P., Stevens, R., Hobbs, F.D.R., Mant, J., Heneghan, C. and McManus, R.J. (2020) ‘Accuracy of blood-pressure monitors owned by patients with hypertension (ACCU-RATE study): a cross-sectional, observational study in central England’, British Journal of General Practice, 70(700), pp. e778–e786. Available at: (Accessed: 28 April 2026).
• Joint Formulary Committee (2026a) ‘Hypertension’, British National Formulary. London: BMJ Group and Pharmaceutical Press. Available at: (Accessed: 28 April 2026).
• Joint Formulary Committee (2026b) ‘Antihypertensive drugs’, British National Formulary. London: BMJ Group and Pharmaceutical Press. Available at: (Accessed: 28 April 2026).
• Joint Formulary Committee (2026c) ‘Drugs affecting the renin-angiotensin system’, British National Formulary. London: BMJ Group and Pharmaceutical Press. Available at: (Accessed: 28 April 2026).
• Joint Formulary Committee (2026d) ‘Calcium-channel blockers’, British National Formulary. London: BMJ Group and Pharmaceutical Press. Available at: (Accessed: 28 April 2026).
• Joint Formulary Committee (2026e) ‘Diuretics’, British National Formulary. London: BMJ Group and Pharmaceutical Press. Available at: (Accessed: 28 April 2026).
• Joint Formulary Committee (2026f) ‘Ramipril’, British National Formulary. London: BMJ Group and Pharmaceutical Press. Available at: (Accessed: 28 April 2026).
• Joint Formulary Committee (2026g) ‘Lisinopril’, British National Formulary. London: BMJ Group and Pharmaceutical Press. Available at: (Accessed: 28 April 2026).
• Joint Formulary Committee (2026h) ‘Losartan potassium’, British National Formulary. London: BMJ Group and Pharmaceutical Press. Available at: (Accessed: 28 April 2026).
• Joint Formulary Committee (2026i) ‘Candesartan cilexetil’, British National Formulary. London: BMJ Group and Pharmaceutical Press. Available at: (Accessed: 28 April 2026).
• Joint Formulary Committee (2026j) ‘Amlodipine’, British National Formulary. London: BMJ Group and Pharmaceutical Press. Available at: (Accessed: 28 April 2026).
• Joint Formulary Committee (2026k) ‘Indapamide’, British National Formulary. London: BMJ Group and Pharmaceutical Press. Available at: (Accessed: 28 April 2026).
• Joint Formulary Committee (2026l) ‘Bendroflumethiazide’, British National Formulary. London: BMJ Group and Pharmaceutical Press. Available at: (Accessed: 28 April 2026).
• Joint Formulary Committee (2026m) ‘Spironolactone’, British National Formulary. London: BMJ Group and Pharmaceutical Press. Available at: (Accessed: 28 April 2026).
• Joint Formulary Committee (2026n) ‘Atenolol’, British National Formulary. London: BMJ Group and Pharmaceutical Press. Available at: (Accessed: 28 April 2026).
• Medicines and Healthcare products Regulatory Agency (MHRA) (2014a) ACE inhibitors and angiotensin II receptor antagonists: not for use in pregnancy. Available at: (Accessed: 28 April 2026).
• Medicines and Healthcare products Regulatory Agency (MHRA) (2014b) ACE inhibitors and angiotensin II receptor antagonists: recommendations on how to use for breastfeeding. Available at: (Accessed: 28 April 2026).
• Medicines and Healthcare products Regulatory Agency (MHRA) (2014c) Clarification: ACE inhibitors and angiotensin II receptor antagonists. Available at: (Accessed: 28 April 2026).
• Medicines and Healthcare products Regulatory Agency (MHRA) (2016) Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia. Available at: (Accessed: 28 April 2026).
• Medicines and Healthcare products Regulatory Agency (MHRA) (2018) Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use. Available at: (Accessed: 28 April 2026).
• National Health Service (NHS) (no date a) High blood pressure. Available at: (Accessed: 28 April 2026).
• National Health Service (NHS) (no date b) Blood pressure test. Available at: (Accessed: 28 April 2026).
• National Health Service (NHS) (no date c) Check your blood pressure reading. Available at: (Accessed: 28 April 2026).
• National Health Service (NHS) (no date d) Find a pharmacy that offers free blood pressure checks. Available at: (Accessed: 28 April 2026).
• NHS England (no date) NHS Community Pharmacy Blood Pressure Check Service. Available at: (Accessed: 28 April 2026).
• NHS England (2023) NHS community pharmacy hypertension case-finding advanced service. Version 2.3. Available at: (Accessed: 28 April 2026).
• National Institute for Health and Care Excellence (NICE) (2019) How do I control my blood pressure? Lifestyle options and choice of medicines: patient decision aid. Available at: (Accessed: 28 April 2026).
• National Institute for Health and Care Excellence (NICE) (2021) Chronic kidney disease: assessment and management. NICE guideline NG203. Available at: (Accessed: 28 April 2026).
• National Institute for Health and Care Excellence (NICE) (2022) Type 1 diabetes in adults: diagnosis and management. NICE guideline NG17. Available at: (Accessed: 28 April 2026).
• National Institute for Health and Care Excellence (NICE) (2023a) Hypertension in pregnancy: diagnosis and management. NICE guideline NG133. Available at: (Accessed: 28 April 2026).
• National Institute for Health and Care Excellence (NICE) (2023b) Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE guideline NG238. Available at: (Accessed: 28 April 2026).
• National Institute for Health and Care Excellence (NICE) (2026) Hypertension in adults: diagnosis and management. NICE guideline NG136. Available at: (Accessed: 28 April 2026).
• Royal College of General Practitioners (RCGP) (2025a) Cardiovascular health. Available at: (Accessed: 28 April 2026).
• Royal College of General Practitioners (RCGP) (2025b) Cardiovascular Health: Supercondensed Curriculum Guide. Available at: (Accessed: 28 April 2026).

Important Disclaimer

This MedDigest MRCGP Topic Essentials is an independent educational and revision resource, created to support exam preparation only. It is not a clinical guideline, prescribing resource, or a substitute for your own professional judgment.

This content is designed to highlight exam-relevant clinical principles, management pathways, and consultation approaches in a concise format. Any example explanations, consultation wording, scenario angles, or summary scripts are illustrative and should not be used as stand-alone clinical advice.

This resource has not been produced, reviewed, or endorsed by NICE, the Royal College of General Practitioners, or any other official organisation.

Medicine and guidance change over time. For definitive recommendations, always consult the latest official guidance, the BNF, and your local clinical policies and referral pathways.

MedDigest and its authors accept no responsibility for any loss, harm, or adverse outcome arising from reliance on the information contained in this resource.